Cargando…
Pneumatocele during sorafenib therapy: first report of an unusual complication
Sorafenib is a multi-kinase inhibitor and a vascular endothelial growth factor (VEGF) inhibitor approved to treat patients with advanced hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma. Its most common side effects are asthenia/fatigue, skin toxicity, diarrhea and...
Autores principales: | Sangro, Paloma, Bilbao, Idoia, Fernández-Ros, Nerea, Iñarrairaegui, Mercedes, Zulueta, Javier, Bilbao, JI, Sangro, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814241/ https://www.ncbi.nlm.nih.gov/pubmed/29464101 http://dx.doi.org/10.18632/oncotarget.23599 |
Ejemplares similares
-
Malignant epithelioid hemangioendothelioma of the liver successfully treated with Sorafenib
por: Sangro, Bruno, et al.
Publicado: (2012) -
Selective internal radiation therapy: an effective treatment for hormonal syndromes in pancreatic neuroendocrine tumors
por: Zubiri, Leyre, et al.
Publicado: (2018) -
Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib
por: Lué, Alberto, et al.
Publicado: (2017) -
Evaluation of the rabbit liver by direct portography and contrast-enhanced computed tomography: anatomical variations of the portal system and hepatic volume quantification
por: Páramo, María, et al.
Publicado: (2017) -
Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials
por: Gardini, Andrea Casadei, et al.
Publicado: (2018)